Precipio (PRPO) AI Stock Analysis

• Market Cap: $29.72M
• Dividend Yield: N/A
• Average Volume (3M): 20.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: 27.05%
• EPS Growth: 55.03%
• Country: US
• Employees: 54
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.05
• Shares Outstanding: 1,619,584
• 10 Day Avg. Volume: 14,640
• 30 Day Avg. Volume: 20,149
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 0.93
• Enterprise Value/Gross Profit: 2.02
• Enterprise Value/Ebitda: -37.59
• 1Y Price Target: $22.00
• Price Target Upside: 11.90% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 62 Neutral
• Price Target: $22.00 ▲(11.90% Upside)

Precipio's overall stock score is driven by strong technical indicators and positive corporate events, which are offset by financial performance challenges and a difficult valuation scenario. The earnings call provided a positive outlook, contributing to the score.

Precipio Business Overview & Revenue Model

Company Description

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

How the Company Makes Money

Precipio generates revenue through multiple streams, including the provision of its molecular diagnostic testing services, which are billed to healthcare providers and patients. The company also earns income from its proprietary technology platform, which offers software solutions for data analysis and reporting in oncology. Key revenue streams include sales from diagnostic tests, licensing agreements for its technology, and partnerships with healthcare institutions that utilize its services. Additionally, collaborations with pharmaceutical companies for clinical trial support and companion diagnostics further contribute to its earnings, enhancing the company's financial stability.

Precipio Financial Statement Overview

Summary

Precipio shows revenue growth and maintains a conservative leverage profile. However, persistent profitability challenges and negative cash flow growth highlight the need for operational improvements.

Income Statement

Precipio's revenue has shown consistent growth, with a 6.27% increase in the TTM period. However, the company continues to face profitability challenges, as indicated by negative net profit and EBIT margins. The gross profit margin has improved slightly, but the overall profitability remains weak.

Balance Sheet

The company maintains a low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is stable, suggesting a solid capital structure despite profitability issues.

Cash Flow

Operating cash flow has improved in the TTM period, but free cash flow growth is negative. The operating cash flow to net income ratio is low, indicating challenges in converting earnings into cash. The free cash flow to net income ratio is relatively strong, suggesting some efficiency in cash management despite overall cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.57M	15.96M	15.20M	9.41M	8.85M	6.09M
Gross Profit	9.49M	7.56M	6.02M	2.51M	2.39M	1.15M
EBITDA	-510.00K	-2.70M	-4.32M	-10.65M	-7.05M	-8.77M
Net Income	-1.80M	-4.29M	-5.85M	-12.20M	-8.55M	-12.23M
Balance Sheet
Total Assets	18.82M	17.00M	18.10M	21.50M	30.44M	20.71M
Cash, Cash Equivalents and Short-Term Investments	1.13M	1.39M	1.50M	3.44M	11.67M	2.66M
Total Debt	2.61M	1.25M	1.12M	1.39M	1.43M	1.49M
Total Liabilities	6.53M	4.90M	3.67M	5.14M	5.83M	6.55M
Stockholders Equity	12.29M	12.09M	14.43M	16.30M	24.56M	14.13M
Cash Flow
Free Cash Flow	565.00K	216.00K	-3.69M	-8.00M	-7.26M	-7.58M
Operating Cash Flow	915.00K	439.00K	-3.56M	-7.72M	-6.58M	-7.43M
Investing Cash Flow	-350.00K	-223.00K	-126.00K	-277.00K	-682.00K	-96.00K
Financing Cash Flow	-714.00K	-329.00K	1.74M	-225.00K	16.27M	9.34M

Precipio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPO, the sentiment is Positive. The current price of 19.66 is above the 20-day moving average (MA) of 18.59, above the 50-day MA of 16.79, and above the 200-day MA of 10.50, indicating a bullish trend. The MACD of 0.73 indicates Positive momentum. The RSI at 57.18 is Neutral, neither overbought nor oversold. The STOCH value of 49.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRPO.

Precipio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	62 Neutral	$29.72M	―	-14.76%	―	27.05%	55.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRIO	49 Neutral	$37.32M	―	-55.06%	―	41.79%	18.45%
BNGO	41 Neutral	$19.32M	―	-118.26%	―	-25.02%	85.08%
TRIB	41 Neutral	$19.23M	―	77.20%	―	-4.02%	-6.31%
INBS	38 Underperform	$10.39M	―	-186.64%	―	-1.90%	87.72%
BIAF	38 Underperform	$4.54M	―	-1802.45%	―	4.99%	22.58%

Precipio Corporate Events

Precipio Ends ATM Agreement with Alliance Global

Precipio, Inc., a specialty cancer diagnostics company, announced the termination of its At-The-Market (ATM) instrument with Alliance Global Partners as of September 2, 2025. This decision reflects the company’s improved financial position, marked by the elimination of negative cash flow and increased cash balance, indicating a reduced reliance on such capital-raising tools and a commitment to enhancing shareholder value.

Precipio Unveils Advancements in AML Diagnostic Technology

On August 18, 2025, Precipio Inc released an updated investor presentation, highlighting its advancements in diagnostic technology, particularly for Acute Myeloid Leukemia (AML). The company’s rapid AML test significantly reduces diagnosis time, offering immediate treatment options and improving patient outcomes. Precipio’s innovative product development platform and profitable clinical lab business support its R&D efforts, addressing industry challenges such as diagnostic errors and delays, and enabling cost-effective solutions with high gross margins.

Precipio Announces Q2-2025 Shareholder Update Call

On July 31, 2025, Precipio, Inc. announced it will host a Q2-2025 Shareholder Update Call on August 14, 2025, at 5:00 PM ET. The call will provide updates on the company’s core businesses, reflecting its commitment to transparency and stakeholder engagement.

Precipio Holds Annual Stockholders Meeting, Approves Proposals

On June 17, 2025, Precipio, Inc. held its Annual Meeting of stockholders, where two key proposals were voted on and approved. The stockholders elected Ilan Danieli and David S. Cohen as Class I directors for terms expiring in 2028 and ratified the appointment of CBIZ CPAs, P.C. as the independent registered public accounting firm for the year ending December 31, 2025.